HOUGHTON MIFFLIN HARCOURT CO (HMHC) Fundamental Analysis & Valuation

NASDAQ:HMHC

Current stock price

21.03
+0.02 (+0.1%)
At close:
21.12
+0.09 (+0.43%)
After Hours:

This HMHC fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. HMHC Profitability Analysis

1.1 Basic Checks

  • In the past year HMHC was profitable.
HMHC Yearly Net Income VS EBIT VS OCF VS FCFHMHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 0 200M -200M -400M

1.2 Ratios

Industry RankSector Rank
ROA 10.82%
ROE 64.63%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HMHC Yearly ROA, ROE, ROICHMHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 0 -100 -200 -300 -400 -500

1.3 Margins

Industry RankSector Rank
OM 5.41%
PM (TTM) 20.32%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HMHC Yearly Profit, Operating, Gross MarginsHMHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 0 20 -20 40 -40

2

2. HMHC Health Analysis

2.1 Basic Checks

  • HMHC has more shares outstanding than it did 1 year ago.
  • The debt/assets ratio for HMHC has been reduced compared to a year ago.
HMHC Yearly Shares OutstandingHMHC Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
HMHC Yearly Total Debt VS Total AssetsHMHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 500M 1B 1.5B 2B 2.5B

2.2 Solvency

  • Based on the Altman-Z score of -1.16, we must say that HMHC is in the distress zone and has some risk of bankruptcy.
  • A Debt/Equity ratio of 0.96 indicates that HMHC is somewhat dependend on debt financing.
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Altman-Z -1.16
ROIC/WACCN/A
WACCN/A
HMHC Yearly LT Debt VS Equity VS FCFHMHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 0 200M 400M 600M 800M

2.3 Liquidity

  • A Current Ratio of 1.39 indicates that HMHC should not have too much problems paying its short term obligations.
  • HMHC has a Quick Ratio of 1.18. This is a normal value and indicates that HMHC is financially healthy and should not expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 1.39
Quick Ratio 1.18
HMHC Yearly Current Assets VS Current LiabilitesHMHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 200M 400M 600M

4

3. HMHC Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 104.02% over the past year.
  • Looking at the last year, HMHC shows a small growth in Revenue. The Revenue has grown by 5.80% in the last year.
  • Measured over the past years, HMHC shows a decrease in Revenue. The Revenue has been decreasing by -4.05% on average per year.
EPS 1Y (TTM)104.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
Revenue 1Y (TTM)5.8%
Revenue growth 3Y-7.38%
Revenue growth 5Y-4.05%
Sales Q2Q%-12.18%

3.2 Future

  • HMHC is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 67.54% yearly.
  • Based on estimates for the next years, HMHC will show a small growth in Revenue. The Revenue will grow by 2.84% on average per year.
EPS Next Y388.14%
EPS Next 2Y201.14%
EPS Next 3Y95.59%
EPS Next 5Y67.54%
Revenue Next Year3.98%
Revenue Next 2Y3.95%
Revenue Next 3Y3.37%
Revenue Next 5Y2.84%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
HMHC Yearly Revenue VS EstimatesHMHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 500M 1B
HMHC Yearly EPS VS EstimatesHMHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

2

4. HMHC Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 300.43 indicates a quite expensive valuation of HMHC.
  • The average S&P500 Price/Earnings ratio is at 26.78. HMHC is valued rather expensively when compared to this.
  • HMHC is valuated quite expensively with a Price/Forward Earnings ratio of 61.55.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.54, HMHC is valued quite expensively.
Industry RankSector Rank
PE 300.43
Fwd PE 61.55
HMHC Price Earnings VS Forward Price EarningsHMHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 100 200 300

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA 10.11
HMHC Per share dataHMHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as HMHC's earnings are expected to grow with 95.59% in the coming years.
PEG (NY)0.77
PEG (5Y)N/A
EPS Next 2Y201.14%
EPS Next 3Y95.59%

0

5. HMHC Dividend Analysis

5.1 Amount

  • No dividends for HMHC!.
Industry RankSector Rank
Dividend Yield N/A

HMHC Fundamentals: All Metrics, Ratios and Statistics

HOUGHTON MIFFLIN HARCOURT CO

NASDAQ:HMHC (4/6/2022, 8:00:02 PM)

After market: 21.12 +0.09 (+0.43%)

21.03

+0.02 (+0.1%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryDiversified Consumer Services
Earnings (Last)02-24
Earnings (Next)05-05
Inst Owners1.13%
Inst Owner Change0%
Ins Owners0.59%
Ins Owner Change0%
Market Cap2.69B
Revenue(TTM)1.05B
Net Income(TTM)213.56M
Analysts45.71
Price Target21.42 (1.85%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 300.43
Fwd PE 61.55
P/S 2.56
P/FCF N/A
P/OCF N/A
P/B 8.13
P/tB N/A
EV/EBITDA 10.11
EPS(TTM)0.07
EY0.33%
EPS(NY)0.34
Fwd EY1.62%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.23
BVpS2.59
TBVpSN/A
PEG (NY)0.77
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 10.82%
ROE 64.63%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM 5.41%
PM (TTM) 20.32%
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3Y0%
ROICexgc growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 0.96
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.39
Quick Ratio 1.18
Altman-Z -1.16
F-Score8
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)104.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%45.45%
EPS Next Y388.14%
EPS Next 2Y201.14%
EPS Next 3Y95.59%
EPS Next 5Y67.54%
Revenue 1Y (TTM)5.8%
Revenue growth 3Y-7.38%
Revenue growth 5Y-4.05%
Sales Q2Q%-12.18%
Revenue Next Year3.98%
Revenue Next 2Y3.95%
Revenue Next 3Y3.37%
Revenue Next 5Y2.84%
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A

HOUGHTON MIFFLIN HARCOURT CO / HMHC Fundamental Analysis FAQ

What is the ChartMill fundamental rating of HOUGHTON MIFFLIN HARCOURT CO (HMHC) stock?

ChartMill assigns a fundamental rating of 6 / 10 to HMHC.


What is the valuation status of HOUGHTON MIFFLIN HARCOURT CO (HMHC) stock?

ChartMill assigns a valuation rating of 3 / 10 to HOUGHTON MIFFLIN HARCOURT CO (HMHC). This can be considered as Overvalued.


What is the profitability of HMHC stock?

HOUGHTON MIFFLIN HARCOURT CO (HMHC) has a profitability rating of 10 / 10.


What are the PE and PB ratios of HOUGHTON MIFFLIN HARCOURT CO (HMHC) stock?

The Price/Earnings (PE) ratio for HOUGHTON MIFFLIN HARCOURT CO (HMHC) is 300.43 and the Price/Book (PB) ratio is 8.13.


How financially healthy is HOUGHTON MIFFLIN HARCOURT CO?

The financial health rating of HOUGHTON MIFFLIN HARCOURT CO (HMHC) is 4 / 10.